Advanced search
Publication Cover
Cancer Management and Research Volume 13, 2021 - Issue
Submit an article Journal homepage
86
Views
0
CrossRef citations to date
0
Altmetric
Original Research

The Effect of Delayed Chemotherapy on the Decrease of CA125 in Epithelial Ovarian Cancer During Coronavirus Disease Pandemic in 2020

Qiang YiDepartment of Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China
,
Yu RanDepartment of Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China
&
Cong LiDepartment of Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8234-2121
ORCID Icon
Pages 515-520 | Published online: 19 Jan 2021

References

  • Frey MK, Ellis AE, Zeligs K, et al. Impact of the coronavirus disease 2019 pandemic on the quality of life for women with ovarian cancer. Am J Obstet Gynecol. 2020;223(5):725.e1–725.e9. doi:10.1016/j.ajog.2020.06.049
  • Rodriguez J, Fletcher A, Heredia F, et al. Alternative management for gynecological cancer care during the COVID-2019 pandemic: a Latin American survey. Int J Gynaecol Obstet. 2020;10:1002. doi:10.1002/ijgo.13272
  • Nakayama J, El-Nashar SA, Waggoner S, et al. Adjusting to the new reality: evaluation of early practice pattern adaptations to the COVID-19 pandemic. Gynecol Oncol. 2020;158(2):SS0090. doi:10.1016/j.ygyno.2020.05.028
  • Bogani G, Casarin J, Pinelli C, et al. Management of patients with ovarian cancer in the COVID-19 era. J Surg Oncol. 2020;122(2):122–123. doi:10.1002/jso.2605732476155
  • Nagel CI, Backes FJ, Hade EM, et al. Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. Gynecol Oncol. 2012;124(2):221–224. doi:10.1016/j.ygyno.2011.10.00322055764
  • Pyeon SY, Han GH, Ki KD, et al. Effect of delayed palliative chemotherapy on survival of patients with recurrent ovarian cancer. PLoS One. 2020;15(7):e0236244. doi:10.1371/journal.pone.023624432701994
  • Yang Z-J, Zhao B-B, Li L. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer. J Ovarian Res. 2016;9(1):57. doi:10.1186/s13048-016-0266-327629537
  • Zeng J, Huang H, Shan Y, et al. The effect of CA125 nadir level on survival of advanced-stage epithelial ovarian carcinoma after interval debulking surgery. J Cancer. 2011;121(2):3410–3415. doi:10.1016/j.ygyno.2011.01.014
  • Pignata S, Cannella L, Leopardo D, et al. Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. Ann Oncol. 2011;22(Suppl 8):viii40–viii44. doi:10.1093/annonc/mdr47022180398
  • Fleming ND, Cass I, Walsh CS, et al. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol. 2011;121(2):249–252. doi:10.1016/j.ygyno.2011.01.01421300398
  • Zeng J, Yin J, Song X, et al. Reduction of CA125 levels during neoadjuvant chemotherapy can predict cytoreduction to no visible residual disease in patients with advanced epithelial ovarian cancer, primary carcinoma of fallopian tube and peritoneal carcinoma. J Cancer. 2016;7(15):2327–2332. doi:10.7150/jca.1676127994671
  • Rustin GJ. Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. Ann Oncol. 2011;22(Suppl 8):viii45–viii48. doi:10.1093/annonc/mdr47122180399
  • Colloca G, Venturino A, Governato I. CA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review. Clin Transl Oncol. 2016;18(8):813–824. doi:10.1007/s12094-015-1441-526546024
  • Chiang AJ, Chen J, Chung Y-C, et al. A longitudinal analysis with CA-125 to predict overall survival in patients with ovarian cancer. J Gynecol Oncol. 2014;25(1):51–57. doi:10.3802/jgo.2014.25.1.5124459581
  • Felder M, Kapur A, Gonzalez-Bosquet J, et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014;13(1):129. doi:10.1186/1476-4598-13-12924886523
  • Dochez V, Caillon H, Vaucel E, et al. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;12(1):28. doi:10.1186/s13048-019-0503-730917847
  • Zhao Z, Zhao X, Lu J, et al. Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies. Arch Gynecol Obstet. 2018;297(4):849–857. doi:10.1007/s00404-018-4678-829368160
  • Saed GM, Diamond MP, Fletcher NM. Updates of the role of oxidative stress in the pathogenesis of ovarian cancer. Gynecol Oncol. 2017;145(3):595–602. doi:10.1016/j.ygyno.2017.02.03328237618

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.